Table 4.
Risk (OR and 95% Cls) of NHL Subtypes by HCV Infection
| Total | Prevalence | |||||
|---|---|---|---|---|---|---|
| n | % | n | % | OR (95% CI)a | P valueb | |
| Lymphoma subtype | ||||||
| Burkitt | 40 | 0.84 | 3 | 7.50 | 2.42 (0.71–8.27) | .75 |
| Diffuse large B-cell lymphoma | 1494 | 31.24 | 76 | 5.09 | 2.24 (1.68–2.99) | .07 |
| LPL | 144 | 3.01 | 7 | 4.86 | 2.57 (1.14–5.79) | .83 |
| MZL | 383 | 8.00 | 17 | 4.44 | 2.47 (1.44–4.23) | .03 |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | 608 | 12.71 | 22 | 3.62 | 1.48 (0.92–2.38) | .31 |
| Other B-cell lymphomac | 244 | 5.10 | 8 | 3.28 | 2.36 (1.11–5.01) | .14 |
| Other T-cell lymphoma | 206 | 4.31 | 6 | 2.91 | 1.41 (0.60–3.29) | .71 |
| NHL NOS | 248 | 5.18 | 7 | 2.82 | 1.50 (0.67–3.33) | .90 |
| FL | 1181 | 24.68 | 23 | 1.95 | 1.02 (0.65–1.60) | .10 |
| M fungoides/Sézary syndrome | 117 | 2.45 | 2 | 1.71 | 0.74 (0.18–3.08) | .41 |
| Mantle cell lymphoma | 119 | 2.49 | 1 | 0.84 | 0.60 (0.08–4.41) | NA |
NOTE. Subtypes are ordered by HCV prevalence.
a
OR and 95% CI were estimated using unconditional logistic regression and a joint fixed-effects model, adjusted for age, sex, race, and study center.
b
Test of heterogeneity between study.
c
Other B-cell lymphoma includes small B-lymphocytic NOS (n = 30), mediastinal large B-cell lymphoma (n = 28), large B-cell immunoblastic (n = 1), B-cell NOS (n = 87), Precursor B NHL (n = 27), other B NHL (n = 60), precursor B-lymphoblastic leukemia or lymphoma (n = 2), hairy cell leukemia (n = 8), and lymphoblastic lymphoma (n = 1).